Background
==========

Stenosis of the proximal segment of the left anterior descending coronary artery (LAD) is a special subgroup of coronary artery disease (CAD), given the high-risk profile that these lesions have alone or in the context of multivessel disease \[[@B1],[@B2]\]. Patients with proximal LAD occlusion in association with low left ventricular ejection fraction have been reported to have 19-fold higher mortality than the general population \[[@B3]\].

The data from previous studies suggest that the outcome after revascularization depends on the distribution of prerevascularization coronary artery disease. In that regard, the severity and location of LAD involvement have been identified as important determinants of outcome in patients with CAD \[[@B4]\]. This lesion carries a high risk of restenosis after balloon angioplasty with reported patency rate at six month-follow-up of approximately 75% \[[@B5]\]. However, some studies have shown that stenting may reduce the rate of restenosis in these lesions in comparison with balloon angioplasty \[[@B6]\]. Specifically, drug-eluting stents have been shown to be related to significantly reduced restenosis rates compared to bare metal stents \[[@B7],[@B8]\].

Numerous studies have investigated the outcome of percutaneous coronary intervention (PCI) and bypass surgery in patients with LAD stenosis \[[@B9]-[@B11]\]. Generally, the presence of a proximal LAD stenosis has swayed the cardiologists to refer the patients to coronary artery bypass grafting (CABG) presuming these lesions have an overall higher rate of restenosis than proximal left circumflex or right coronary artery \[[@B12]\]. However, according to the American College of Cardiology/American Heart Association, only type B2/C lesions of the LAD carry a high risk of target vessel revascularization (TVR) and morbidity \[[@B13]\] and surgery has been proposed as a better option only for such lesions \[[@B14]\]. According to the 2003 report from the Iranian Statistical Center, 14100 PCI procedures were performed in 50 hospitals in Iran. Of these, approximately 1700 procedures were carried out in Tehran Heart Center (THC). Because of the clinical significance of the lesions located in proximal LAD, our objective in this study was to evaluate the procedural results, in-hospital and long-term clinical outcomes of PCI on proximal LAD, proximal left circumflex (LCX) or right coronary artery(RCA), and non-proximal LAD.

Methods
=======

Study population
----------------

From a total of 1737 consecutive patients undergoing PCI at THC between March 2004 and March 2005, a patient cohort with PCI for de novo narrowing in the proximal segments of coronary arteries or non-proximal LAD were included in the study. Patients with cardiogenic shock, primary PCI, total occlusions, and multivessel or multi-lesion PCI were excluded. Among the 785 remaining patients: 408 had PCI on proximal LAD, 133 underwent PCI on proximal LCX or RCA, and 244 patients were treated with PCI on non-proximal LAD. In study I (n = 541), we compared the outcomes of PCI on proximal LAD versus proximal LCX/RCA. In study II (n = 652), the outcome of PCI on proximal LAD versus non-proximal LAD were compared. Baseline, clinical, angiographic, and procedural characteristics plus in-hospital outcomes were obtained by research physicians and entered into a computerized database by computer operators. Finally, 449 patients in study I and 549 patients in study II agreed to participate in follow-up programs. They were monitored by cardiologists 1, 5, and 9 months post angioplasty and once a year thereafter. Patient follow up was done in the clinic or by formal telephone interviews. Clinical data obtained were: major adverse cardiac events (MACE), including cardiac death, non-fatal myocardial infarction (MI), and TVR (CABG or repeated PCI). The data were recorded in data sheets and later transferred into a computerized database. This study was approved by the THC Ethics Committee. Informed consent was obtained from patients before enrolment into this study.

Definitions
-----------

Patients already taking hypertensive medication or those whose average of two blood pressure readings at least five minutes apart in the sitting posture was ≥ 140/90 mmHg were labeled as hypertensive \[[@B15]\]. Patients with a history of taking antihyperlipidemic drugs, total cholesterol ≥ 200 mg/dl or low density lipoprotein ≥ 130 mg/dl were defined as hypercholestrolemic \[[@B16]\]. Diabetes mellitus was diagnosed to be present if a patient had a definite history of treated diabetes, fasting plasma glucose ≥ 126 mg/dl or two-hour post-load glucose ≥ 200 mg/dl, based on the guidelines of the American Diabetes Association \[[@B17]\]. Angina symptoms were defined according to the classification of the Canadian Cardiovascular Society \[[@B18]\]. Lesion types were noted according to the American College of Cardiology/American Heart Association (ACC/AHA) lesion characteristics classification \[[@B19]\]. Left ventricular ejection fraction was obtained from cardiac catheterization ventriculograms. Q wave MI was defined as the presence of new Q waves in post-procedure electrocardiograms with a 3-fold increase in MB fraction of creatinine kinase. Non-Q wave MI was defined as a 3-fold increase in MB fraction of creatinine kinase without the development of new Q waves \[[@B20]\]. Angiographic success was defined as residual stenosis \<20% for stenting and \<50% for balloon angioplasty plus normal Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Procedural success was defined as angiographic success without major complications (death, MI, emergency CABG or PCI) during hospitalization \[[@B19]\]. Major adverse cardiac events were defined as the presence of cardiac death, MI, and TVR during follow-up. TVR was defined as ischemia-driven repeat percutaneous intervention or bypass surgery of the target vessel. Target lesion revascularization (TLR) was defined as ischemia-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel \[[@B21]\]. Proximal stenosis was defined as stenosis located between the origin of the vessel to the takeoff of the first side branch (first diagonal branch for LAD).

Coronary procedures
-------------------

Patients received 325 mg of Aspirin before the procedure, which was continued indefinitely. Coronary stenting was performed by standard methods. After stent placement, ticlopidine (250 mg twice daily) or clopidogrel (75 mg once daily) was given routinely for 4 weeks for bare metal stents and 6 to 12 months for drug-eluting stents. Glycoprotein IIb/IIIa blocker was not used in any patient. Angiographic findings such as vessel dimensions, pre-and post-procedural stenoses, lesion length, and TIMI flow grade were determined by visual estimation using the guiding catheter as a reference object for calibration. The angiographic characteristics were also further analyzed by an independent interventional cardiologist not involved in the procedure and checked for inter-observer agreement (kappa coefficient = 0.91, 95% CI = 0.85--0.97).

Statistical analysis
--------------------

Statistical testing was performed by chi-square test or Fisher\'s exact test (2-tailed) for categorical variables. Student\'s t-test was used for comparison of continuous variables. Because of the imbalances in some baseline characteristics, the main study results were confirmed by means of stratified analyses and multivariate logistic regression models. Stratification was performed for variables that either had significant imbalance between the groups (p \< 0.05), or were clinically important. These variables included sex, diabetes mellitus, prior PCI, use of drug-eluting stents, angulated segments, stent length, and stent diameter. Furthermore, we constructed multivariate logistic regression models with selected variables that had p values \< 0.05 in univariate analysis (sex and use of drug-eluting stents were also included). The p values of these variables are marked in bold l in tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Long-term MACE modeling was performed with Cox proportional hazards model. The statistical analyses were performed with SAS software version 9.1. Differences were considered statistically significant at p values \< 0.05.

Results
=======

Baseline characteristics
------------------------

Table [1](#T1){ref-type="table"} represents selected baseline characteristics of patients treated for proximal stenoses of major epicardial arteries and non-proximal LAD. Current smoking and prior non-target vessel PCI had a lower frequency in patients with PCI on proximal LAD versus LCX or RCA. However, in patients with PCI on proximal versus non-proximal LAD, the baseline demographic characteristics did not differ. Mean Ejection Fraction was 53.54 ± 9.45% in the proximal LAD versus 53.12 ± 10.24% and 54.35 ± 9.22% in the proximal LCX/RCA and non-proximal LAD groups (p = NS), respectively. In the proximal LAD versus proximal LCX/RCA and non-proximal LAD, the frequency of unstable angina (33.7% vs. 34.8% and 33.7%) and prior MI (33.8% vs. 28.6% and 29.5%) had no statistically significant difference (P = NS).

Angiographic and procedural characteristics (Table [2](#T2){ref-type="table"})
------------------------------------------------------------------------------

Frequency of type B2/C lesions was similar in the proximal LAD vs. proximal LCX/RCA and non-proximal LAD groups: (42.8% vs.43.8% and 47.8, p = NS). Multivessel disease and angulated segments were less frequent in the proximal LAD group. In the proximal LAD versus proximal LCX/RCA group, lesions were longer (16.89 ± 8.1 mm versus 14.68 ± 7.38 mm, p = 0.007) and had lower frequency of proximal segment tortuosity (p = 0.03). However, percentage of lesions smaller than 3 mm in diameter did not differ. On the other hand, in the proximal versus non-proximal LAD group, expectedly, lesions had larger reference vessel diameters. Stents were used in 99.8% of patients in the proximal LAD versus 98.5% in the proximal LCX/RCA (p = NS) and 96.7% in the non-proximal LAD groups (p = 0.002). Pre- and post-procedural stenosis percentages did not differ significantly in the proximal LAD versus proximal LCX/RCA and non-proximal LAD groups (89.44 ± 8.65% versus 89.15 ± 9.37% and 89.96 ± 8.28%; 0.65 ± 3.24% versus 2.75 ± 13.69% and 1.11 ± 4.51%, p = NS). Patients with PCI on proximal LAD versus proximal LCX/RCA were more commonly treated with drug-eluting stents and had longer stents with smaller diameters. Patients with proximal versus non-proximal LAD stenosis were more often treated with stents, especially the direct stenting technique.

In-hospital and late clinical outcomes
--------------------------------------

In the proximal LAD group, procedures were angiographically successful in 100% of cases, which was significantly greater than the other two groups. In-hospital events, which occurred only as non-Q wave MI in our cohort, were observed in 8 (2%) in the proximal LAD group, while only 1 patient in the proximal LCX/RCA and non-proximal LAD group (0.8% and 0.4% respectively) displayed such symptoms(P = NS). Procedural success rates were similar in both comparisons (table [3](#T3){ref-type="table"}). Mean follow-up duration was 10.81 ± 3.69 months in total population. Major adverse cardiac events at 9-month follow-up, including cardiac death, MI, and TVR (CABG or repeated PCI) were not significantly different in the proximal LAD versus the other two groups (table [3](#T3){ref-type="table"}). After stratification for factors that either had significant imbalance between the groups or were clinically important, the MACE rates in the proximal LAD versus proximal LCX/RCA and non-proximal LAD groups were still comparable (table [4](#T4){ref-type="table"}). Similarly, in multivariate logistic regression models, there was no difference in MACE rates in the proximal LAD versus proximal LCX/RCA (p = 0.85, 95% CI = 0.19--3.89, OR = 0.87) and proximal versus non-proximal LAD groups (p = 0.66, 95% CI = 0.29--2.1, OR = 0.8). Cox proportional hazards model also did not show any difference in MACE-free survival rates at long-term follow-up (figure [1](#F1){ref-type="fig"}).

Discussion
==========

The main finding that emerges from this study is that long-term outcomes of PCI including MACE in patients with proximal LAD stenosis are similar to patients with proximal LCX or RCA and non-proximal LAD stenosis. Also worth noting from our findings was that angiographic success was higher in patients with proximal LAD stenosis.

Management of proximal coronary artery disease is important due to the large areas of myocardium that lie downstream of the stenoses. The proximal LAD artery stenosis represents the most important proximal site for obstructive coronary artery after left main stem lesion disease, as it supplies 40%--50% of the total left ventricular myocardium and could result in ischemia to a large area of myocardium \[[@B22],[@B23]\]. Moreover, Patients with a critical stenosis of the proximal LAD segment are particularly prone to adverse effects of MI and, therefore, require a safe and long-term effective method of treatment \[[@B24]\].

Previous studies have demonstrated that interventional treatment produces are more beneficial than pharmacological treatment in severe proximal LAD artery disease \[[@B6]\]. However, The results of nonstenting PCI to proximal LAD stenoses has been less satisfactory than procedures in the proximal right/circumflex coronary arteries due to higher rates of restenosis in this area \[[@B12],[@B25],[@B26]\]. Stenting leads to better clinical outcomes than percutaneous transluminal coronary angioplasty in the treatment of isolated lesions of proximal LAD by reducing the risk of restenosis by about 50% \[[@B3]\]. In fact, stenting of lesions in the proximal LAD is as effective and safe as treatment of lesions located in distal LAD. Therefore, in the current stenting era, location of the lesion in the LAD is not predictive of worse outcome. Furthermore, when stenting is feasible, it may not be taken into account in the choice of revascularization strategy \[[@B27]\]. However, the re-intervention rates have been higher after bare-metal stenting than bypass surgery of the proximal LAD \[[@B28]\]. With the advent of drug-eluting stents, a reduction has been achieved in restenosis rates after stenting in proximal LAD. This in turn has narrowed the \"reintervention gap\" between drug-eluting stents enough to eliminate the major advantage of bypass surgery for the treatment of LAD disease \[[@B7]\].

In our study, no significant difference was observed in rates of major adverse cardiac events during long-term follow-up in the proximal LAD versus the other two groups. Even after adjusting for factors such as stents, particularly drug-eluting stents, which were used most frequently in the proximal LAD group, no statistical difference was detectible. MACE-free survival rates were also similar between the groups (figure [1](#F1){ref-type="fig"}). Before our study, Ashby et al had studied the outcomes of stenting in proximal LAD versus proximal LCX/RCA \[[@B12]\]. In their study, multivariate analysis was conducted to adjust these groups for some baseline differences. However, the main endpoint of this study i.e. rate of TLR, was still similar in both groups in patients treated with stents. Before that, The Stent Restenosis (STRESS) study had shown that irrespective of the procedure used (balloon angioplasty or stenting), the most important predictors of the larger luminal diameter at follow-up were the size of the luminal diameter after the procedure, the initial reference vessel diameter, and the location of a lesion in a vessel other than LAD \[[@B29]\].

As a secondary aim, we found that angiographic success rate was higher in patients with proximal LAD stenoses. This may be attributed to better accessibility of lesions and higher frequency of stent use in the proximal LAD group. However, because of the paucity of procedural failure rates, this effect could not be proven by means of statistical analyses.

One of the limitations of this study was the relatively small sample size of patients who had developed complications, which made it difficult to determine the predictors of MACE from the multivariate analysis. On the other hand, we had to exclude patients with multi-lesion or multivessel percutaneous coronary intervention, because otherwise we would not have been able to attribute MACE to a particular lesion site.

Conclusion
==========

In our study, there was no difference in the short- and long-term clinical outcomes of PCI (MACE and its components) on proximal LAD versus proximal parts of other major epicardial arteries and non-proximal LAD. However, acute angiographic success rate was higher in patients with proximal LAD lesions. After adjusting the groups for significant baseline differences, there was still no difference in clinical outcomes between these groups.
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![**MACE-free survival rates in the proximal LAD versus proximal LCX/RCA and non-proximal LAD groups**. MACE = Major adverse cardiac events.](1471-2261-7-7-1){#F1}

###### 

Selected baseline characteristics in the Proximal LAD versus Proximal LCX/RCA and Non-proximal LAD groups

                                  **Proximal LAD n = 408**   **Proximal LCX/RCA n = 133**   **P value (study I) \***   **Non-proximal LAD n = 244**   **P value (study II) \*\***
  ------------------------------- -------------------------- ------------------------------ -------------------------- ------------------------------ -----------------------------
  Age(yrs) (mean ± SD)            55.36 ± 10.87              56.94 ± 9.7                    0.14                       55.6 ± 10.88                   0.78
  Male                            285(69.9%)                 104(78.2%)                     **0.06**                   163(66.8%)                     0.41
  Diabetes Mellitus               76(19.1%)                  33(25.4%)                      0\. 12                     58 (24%)                       0.14
  Family history of CAD           89(21.8%)                  21(15.8%)                      0.13                       54(22.1%)                      0.91
  hypercholesterolemia            171(43%)                   59(45.4%)                      0.63                       107(44.2%)                     0.76
  Current smoker                  157(38.5%)                 68(51.1%)                      **0.01**                   86(35.2%)                      0.41
  hypertension                    132(33.2%)                 38(29.2%)                      0.4                        92(38%)                        0.21
  Myocardial infarction           138 (33.8%)                38 (28.6%)                     0.26                       72 (29.5%)                     0.25
  Prior PCI (Non-target vessel)   15(3.7%)                   12(9%)                         **0.01**                   7(2.9%)                        0.58
  Prior CABG                      2(0.5%)                    2(1.5%)                        0.24                       1(0.4%)                        \>0.999

CAD = coronary artery disease

PCI = percutaneous coronary intervention

CABG = coronary artery bypass grafting

\* Proximal LAD group vs proximal LCX/RCA group

\*\* Proximal LAD group vs non-proximal LAD group

Variables with p values that are marked in bold were entered into multivariate analysis.

###### 

Angiographic and procedural characteristics in the Proximal LAD versus Proximal LCX/RCA and Non-proximal LAD groups

                                     **Proximal LAD n = 408**   **Proximal LCX/RCA n = 133**   **P value (study I) \***   **Non-proximal LAD n = 244**   **P value (study II) \*\***
  ---------------------------------- -------------------------- ------------------------------ -------------------------- ------------------------------ -----------------------------
  **Angiographic characteristics**                                                                                                                       
   Multivessel disease               110 (33.1%)                64 (61.5%)                     **\<0.001**                85 (41.5%)                     **0.05**
   Type B2/C                         169 (42.8%)                56 (43.8%)                     0.85                       110 (47.8%)                    0.22
   Angulated segments (\>45°)        9 (2.2%)                   18 (13.5%)                     **\<0.001**                17 (7%)                        **0.003**
   Tubular lesions                   221(54.2%)                 53 (39.8%)                     0.004                      118 (48.4%)                    0.15
   Proximal tortuoisity              2 (0.5%)                   4 (3%)                         0.035                      2 (0.8%)                       0.6
   RVD (\<3 mm)                      85 (21.6%)                 21 (16.2%)                     0.18                       109 (46.6%)                    **\<0.001**
  **Procedural characteristics**                                                                                                                         
   Direct stenting technique         251(61.5%)                 82 (62.6%)                     0.33                       122(50.4%)                     **\<0.001**
   Drug-eluting stents               97 (24.3%)                 9 (7.2%)                       **\<0.001**                39 (17.2%)                     **0.079**
   Stent length(mm), mean ± SD       18.48 ± 6.79               16.68 ± 6.69                   **0.009**                  18.54 ± 6.77                   0.9
   Stent diameter(mm), mean ± SD     3.08 ± 6.79                3.23 ± 0.39                    **\<0.001**                2.88 ± 6.76                    **\<0.001**

RVD = reference vessel diameter (estimated visually)

\* Proximal LAD group vs Proximal LCX/RCA group

\*\* Proximal LAD group vs Non-proximal LAD group

Variables with p values that are marked in bold were entered into multivariate analysis.

###### 

In-hospital and late outcomes of PCI in the Proximal LAD versus Proximal LCX/RCA and Non-proximal LAD groups

                                 **Proximal LAD n (%)**   **Proximal LCX/RCA n (%)**   **P value (study I) \***   **Non-proximal LAD n (%)**   **P value (study II) \*\***
  ------------------------------ ------------------------ ---------------------------- -------------------------- ---------------------------- -----------------------------
  **In-hospital outcomes**       **n = 408**              **n = 133**                                             **n = 244**                  
  Angiographic Success           408 (100%)               129 (97%)                    0.004                      241 (98.8%)                  0.05
  Procedural Success             400 (98%)                128 (96.2%)                  0.10                       240 (98.4%)                  \>0.999
  In-hospital Events             8 (2%)                   1 (0.8%)                     0.45                       1 (0.4%)                     0.27
  **9-month follow-up**          **n = 338**              **n = 111**                                             **n = 211**                  
  Major adverse cardiac events   11 (3.3%)                3 (2.7%)                     \>0.999                    12 (5.7%)                    0.17
   Cardiac death                 1 (0.3%)                 1 (0.9%)                     0.43                       2 (0.9%)                     0.56
   Non-fatal MI                  4(1.2%)                  1 (0.9%)                     \>0.999                    2 (0.9%)                     \>0.999
   TVR                           6 (1.8%)                 2 (1.8%)                     \>0.999                    7 (3.3%)                     0.17
    TLR                          2 (0.6%)                 1 (0.9%)                     0.57                       2 (0.9%)                     0.63
    CABG                         4 (1.2%)                 1 (0.9%)                     \>0.999                    5 (2.4%)                     0.29

MI = myocardial infarction

CABG = coronary artery bypass grafting

TVR = target vessel revascularization

TLR = target lesion revascularization

\* Proximal LAD group vs Proximal LCX/RCA group

\*\* Proximal LAD group vs Non-proximal LAD group

###### 

Rate of long-term follow-up Major adverse cardiac events and Odds ratios in the patient subgroups

                            **Proximal LAD**No./total (%)   **Proximal LCX/RCA**No./total (%)   **Odds Ratio\* (95% CI) Study I**   **Non-proximal LAD**No./total(%)   **Odds Ratio\*\* (95% CI) Study II**
  ------------------------- ------------------------------- ----------------------------------- ----------------------------------- ---------------------------------- --------------------------------------
  **Sex**                                                                                                                                                              
   male                     7/235 (3.2)                     3/88(3.4)                           0.9(0.2--3.4)                       9/143(6.3)                         0.5 (0.2--1.2)
   female                   4/103 (3.9)                     0/23                                \-                                  3/68(4.4)                          0.9(0.2--4.0)
  **Diabetes mellitus**                                                                                                                                                
   Yes                      1/66(1.5)                       0/28                                \-                                  4/52(7.7)                          0.2(0.1--1.7)
   No                       10/373(3.6)                     3/82(3.7)                           1.0(0.3--3.8)                       8/157(5.1)                         0.7(0.3--1.9)
  **Prior PCI**                                                                                                                                                        
   Yes                      0/12                            0/11                                \-                                  0/6                                \-
   No                       11/326(3.3)                     3/100(3.0)                          1.1(0.4--4.1)                       12/205(5.9)                        0.6(0.2--1.3)
  **Drug-eluting stents**                                                                                                                                              
   Yes                      2/83(2.4)                       0/6                                 \-                                  1/37(2.7)                          0.8(0.1--9.5)
   No                       9/260(3.5)                      3/100(3.0)                          1.2(0.4--4.5)                       11/169(6.5)                        0.6(0.2--1.4)
  **Angulated segments**                                                                                                                                               
   Yes                      0/7                             0/16                                \-                                  0/15                               \-
   No                       11/331 (3.3)                    3/95(3.2)                           1.1(0.3--3.8)                       12/196(6.2)                        0.5(0.3--1.2)
  **Stent length**                                                                                                                                                     
   \<20 mm                  10/270(3.7)                     3/94(3.2)                           1.2(0.4--4.3)                       8/146(5.4)                         0.7(0.3--1.8)
   \>20 mm                  1/68(1.5)                       0/1                                 \-                                  4/55(7.3)                          0.2(0.1--1.7)
  **Stent diameter**                                                                                                                                                   
   \<3 mm                   6/73(8.2)                       0/15                                \-                                  7/97(7.2)                          1.4(0.4--4.4)
   \>3 mm                   5/260(1.9)                      3/98(3.1)                           0.6(0.1--2.6)                       5/100(5.0)                         0.4(0.1--1.4)

PCI = percutaneous coronary intervention

CI = Confidence Interval

\* Odds Ratio for MACE in the Proximal LAD vs. Proximal LCX/RCA group

\*\* Odds Ratio for MACE in the Proximal LAD vs. Non-proximal LAD group
